Prolonged Transcutaneous Tibial Nerve Stimulation for Pediatric Overactive Bladder

Overview

This prospective single-group study evaluated the efficacy of extending transcutaneous tibial nerve stimulation (TTNS) treatment to 24 weeks in children with overactive bladder (OAB). Results suggest that prolonged TTNS may provide incremental benefits, including symptom improvement in early nonresponders.

Background

Pediatric overactive bladder (POAB) is characterized by urgency, urinary incontinence, and increased voiding frequency without infection or organic pathology, affecting up to 12% of children aged 5–10 years. POAB is associated with social and psychological difficulties and often persists into adulthood. Current treatments include behavioral therapies and pharmacologic agents, but many children do not achieve satisfactory symptom control. TTNS is a noninvasive neuromodulation technique showing promise in adults and children, yet evidence on optimal treatment duration in pediatrics is limited.

Data Highlights

The study enrolled children aged 6 to 18 years with POAB symptoms confirmed by Overactive Bladder Symptom Score (OABSS) criteria. Participants underwent home-based TTNS with assessments at baseline, 12 weeks, and 24 weeks. Key inclusion criteria included urgency score ≥ 2 and total OABSS ≥ 3, with symptoms persisting ≥ 3 months. Pharmacologic treatments were withheld during the study to avoid confounding. No prior tibial nerve neuromodulation was reported among participants.

Key Findings

• TTNS administered over 24 weeks demonstrated sustained and potentially enhanced symptom relief compared to the conventional 12-week course.
• Children who did not respond by 12 weeks showed improvement by 24 weeks, indicating the presence of late responders.
• TTNS was well tolerated with good adherence due to its noninvasive and wearable nature.
• Structured urotherapy remained the first-line treatment, with TTNS positioned as a second-line adjunct for persistent symptoms.
• Pharmacologic confounding was minimized by requiring a washout period and prohibiting medication initiation during the study.

Clinical Implications

Extending TTNS treatment to 24 weeks may enhance clinical outcomes in pediatric OAB, particularly benefiting children who do not initially respond within 12 weeks. Clinicians should consider prolonged TTNS as a safe, noninvasive adjunct to urotherapy before escalating to pharmacologic or invasive interventions. Monitoring adherence and symptom progression at multiple time points can help identify late responders and optimize individualized care.

Conclusion

Prolonged TTNS treatment up to 24 weeks appears to provide incremental benefits in managing pediatric overactive bladder, including symptom improvement in early nonresponders. This supports the integration of extended neuromodulation therapy into stepwise pediatric OAB management.

References

1. International Children’s Continence Society (ICCS) -- Definitions and Guidelines
2. Swedish Epidemiological Study -- Prevalence of Pediatric OAB
3. Recent TTNS Studies -- Efficacy in Pediatric OAB
4. Qilu Hospital Prospective Study Protocol -- TTNS for POAB